"From Failures to Hope: FDA Approves Groundbreaking Alzheimer's Drug"

Eisai, the Japanese biotech company behind the newly approved Alzheimer's drug Leqembi, sees the approval as a catalyst in a competitive market. Leqembi showed a 27% reduction in cognitive decline in patients after 18 months and received full approval, expanding access for Alzheimer's patients. However, competitor Eli Lilly announced its treatment, donanemab, showed a 35% reduction in cognitive decline. Both drugs target the reduction of beta-amyloid plaques in the brain. Eisai is focused on expanding access for Leqembi to earlier-stage patients and believes it has set the bar for competitors in terms of price and data transparency.